keyword
MENU ▼
Read by QxMD icon Read
search

Dulaglutide

keyword
https://www.readbyqxmd.com/read/29765207/adherence-to-antihyperglycemic-medications-and-glucagon-like-peptide-1-receptor-agonists-in-type-2-diabetes-clinical-consequences-and-strategies-for-improvement
#1
REVIEW
Francesco Giorgino, Alfred Penfornis, Valeria Pechtner, Raffaella Gentilella, Antonella Corcos
Adherence to antihyperglycemic medications is often suboptimal in patients with type 2 diabetes, and this can contribute to poor glycemic control, increased hospitalization, and the development of diabetic complications. Reported adherence rates to antihyperglycemics vary widely among studies, and this may be related to differences in methodology for measuring adherence, patient populations, and other factors. Poor adherence may occur regardless of the specific regimen used and whether therapy is oral or injectable, and can be especially common in chronic, asymptomatic conditions, such as type 2 diabetes...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29760945/liraglutide-and-dulaglutide-therapy-in-addition-to-sglt-2-inhibitor-and-metformin-treatment-in-indian-type-2-diabetics-a-real-world-retrospective-observational-study
#2
S Ghosal, B Sinha
Background: Therapy for Type 2 diabetes (T2D) has been transformed by the introduction of newer agents like Glucagon like Peptide Receptor Agonists (GLP-1RA) and Sodium-glucose linked transporter inhibitors (SGLT2i). However with co-initiation of SGLT2i and GLP-1RA in the DURATION 8 trial an improvement in HbA1c was noted but the beneficial effect was not equal to the sum of its parts. In view of this we proceeded to test the hypothesis that sequential addition of GLP-1RA therapy to metformin and SGLT-2i may be more beneficial...
2018: Clinical Diabetes and Endocrinology
https://www.readbyqxmd.com/read/29756388/semaglutide-for-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#3
Panagiotis Andreadis, Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, Aris Liakos, Apostolos Manolopoulos, Eleni Bekiari, David R Matthews, Apostolos Tsapas
AIM: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. METHODS: We searched major electronic databases and grey literature sources for randomised controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c . Secondary endpoints included change from baseline in body weight, blood pressure, heart rate, and incidence of hypoglycaemia, gastrointestinal adverse effects, pancreatitis and diabetic retinopathy...
May 13, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29708650/efficacy-and-safety-of-dulaglutide-monotherapy-compared-to-glimepiride-in-east-asian-patients-with-type-2-diabetes-in-a-multicenter-double-blind-randomized-parallel-arm-active-comparator-phase-3-trial
#4
Yu Hong Chen, Chien-Ning Huang, Young Min Cho, Pengfei Li, Liqun Gu, Feng Wang, Jun Yang, Wei Qing Wang
AIMS: To compare the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide 1.5 mg and 0.75 mg with glimepiride in East Asian (EA) patients with type 2 diabetes (T2D). MATERIALS AND METHODS: In this phase 3, multinational, multicenter, double-blind, randomized, parallel-arm 26-week study, patients with inadequate glycemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 mg or 0.75 mg or daily glimepiride (1-3 mg/day)...
April 30, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29693361/generalizability-of-glucagon-like-peptide-1-receptor-agonist-cardiovascular-outcome-trials-enrollment-criteria-to-the-us-type-2-diabetes-population
#5
Eric T Wittbrodt, James M Eudicone, Kelly F Bell, Devin M Enhoffer, Keith Latham, Jennifer B Green
OBJECTIVES: Cardiovascular outcomes trials (CVOTs) for evaluating the safety of novel antidiabetic agents are required by the FDA. CVOTs vary in their design and inclusion criteria, making it difficult to evaluate their applicability to the general population. This study examined the proportion of adults eligible for 7 ongoing or completed glucagon-like peptide-1 receptor agonist (GLP-1 RA) CVOTs. STUDY DESIGN: This cross-sectional, retrospective, cohort study compared data from the National Health and Nutrition Examination Survey (NHANES) with published eligibility criteria from GLP-1 RA CVOTs...
April 2018: American Journal of Managed Care
https://www.readbyqxmd.com/read/29661026/patient-perceptions-of-injection-devices-used-with-dulaglutide-and-liraglutide-for-treatment-of-type-2-diabetes
#6
Louis S Matza, Kristina S Boye, Brooke M Currie, Rosirene Paczkowski, Laura F Lando, Reema Mody, Jessica Jordan
OBJECTIVE: Liraglutide and dulaglutide have demonstrated similar glycemic efficacy and safety; however, they differ in treatment administration and injection devices. The purpose of this study was to examine and compare patient perceptions of the injection devices used with liraglutide and dulaglutide. METHODS: Patients with type 2 diabetes treated with liraglutide or dulaglutide were recruited from across the US. Patients completed the Diabetes Injection Device Experience Questionnaire (DID-EQ) to rate their current injection device...
April 16, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29603872/effect-of-once-weekly-dulaglutide-by-baseline-beta-cell-function-in-people-with-type-2-diabetes-in-the-award-programme
#7
Chantal Mathieu, Stefano Del Prato, Fady T Botros, Vivian T Thieu, Imre Pavo, Nan Jia, Axel Haupt, Chrisanthi A Karanikas, Luis-Emilio García-Pérez
Glucagon-like peptide-1 receptor agonists lower blood glucose in T2D partially through glucose-dependent stimulation of insulin secretion. The aim of the study was to investigate whether or not beta-cell function (measured by HOMA2-%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide-treated patients from AWARD-1, AWARD-3 and AWARD-6 clinical studies were categorised based on their homeostatic model assessment of beta-cell function (HOMA2-%B) tertiles. Changes in glycaemic measures in response to treatment with once-weekly dulaglutide were evaluated in each HOMA2-%B tertile...
March 30, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29574633/a-network-meta-analysis-comparing-semaglutide-once-weekly-with-other-glp-1-receptor-agonists-in-japanese-patients-with-type-2-diabetes
#8
Neil Webb, Michelle Orme, Michal Witkowski, Rie Nakanishi, Jakob Langer
INTRODUCTION: Semaglutide once-weekly (QW) is a novel glucagon-like peptide-1 (GLP-1) analogue administered at a 0.5 or 1.0 mg dose. In the absence of head-to-head trials between semaglutide QW and other GLP-1 receptor agonists (GLP-1 RAs) in a Japanese population, a network meta-analysis (NMA) was performed. The objective was to assess the relative efficacy and safety of semaglutide QW vs GLP-1 RAs in Japanese patients with type 2 diabetes (T2DM), with a specific focus on the comparison between semaglutide 0...
March 24, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29557057/cost-of-achieving-hba1c-treatment-targets-and-weight-loss-responses-with-once-weekly-semaglutide-versus-dulaglutide-in-the-united-states
#9
Lars Wilkinson, Barnaby Hunt, Pierre Johansen, Neeraj N Iyer, Tam Dang-Tan, Richard F Pollock
INTRODUCTION: The National Health and Nutrition Examination Surveys show that many people with type 2 diabetes (T2D) in the USA fail to achieve recommended treatment targets. In the SUSTAIN 7 randomized controlled trial, once-weekly semaglutide (0.5 and 1.0 mg) was superior to comparative doses of dulaglutide (0.75 and 1.5 mg) in reducing glycated hemoglobin (HbA1c) and body weight in people with T2D. The present study estimated the cost per patient achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide and dulaglutide in the USA...
March 19, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29530008/hyperglycemia-related-central-pontine-demyelinization-after-a-binge-eating-attack-in-a-patient-with-type-2-diabetes-a-case-report
#10
Rainer U Pliquett, Arno Noll, Richard Ibe, Alexandra Katz, Charlotte Ackmann, Alexandra Schreiber, Matthias Girndt
BACKGROUND: Here, we report a case of central pontine demyelinization in a type-2 diabetes patient with hyperglycemia after a binge-eating attack in the absence of a relevant hyponatremia. CASE PRESENTATION: A 55-year-old, male type-2 diabetic patient with liver cirrhosis stage Child-Pugh B was admitted due to dysmetria of his right arm, gait disturbance, dizziness, vertigo, and polyuria, polydipsia after a binge-eating attack of sweets (a whole fruit cake and 2 Liters of soft drinks)...
March 12, 2018: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/29525885/utilization-patterns-of-glucagon-like-peptide-1-receptor-agonists-in-patients-with-type-2-diabetes-mellitus-in-italy-a-retrospective-cohort-study
#11
Marco Orsini Federici, Janette McQuillan, Giovanni Biricolti, Serena Losi, Jeremie Lebrec, Catrina Richards, Cristiana Miglio, Kirsi Norrbacka
INTRODUCTION: Real-world evidence on glucagon-like peptide-1 receptor agonist (GLP-1 RAs) usage is emerging in different European countries but is lacking in Italy. This retrospective cohort study aimed to describe the real-world drug utilization patterns in patients initiating GLP-1 RAs for treating T2DM in Italy. METHODS: Adults aged ≥ 20 years and with ≥ 1 oral antidiabetic drug (alone or in combination with insulin) other than GLP-1 RAs in the 6 months prior to initiating exenatide twice daily (exBID), exenatide once weekly (exQW), dulaglutide once weekly (DULA), liraglutide once daily (LIRA) or lixisenatide once daily (LIXI) between March and July 2016 were retrospectively identified in the Italian IMS LifeLink™ longitudinal prescriptions database (retail pharmacy data)...
April 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29525225/durability-of-protective-effect-of-dulaglutide-on-pancreatic-%C3%AE-cells-in-diabetic-mice-glp-1-receptor-expression-is-not-reduced-despite-long-term-dulaglutide-exposure
#12
T Kimura, A Obata, M Shimoda, H Hirukawa, Y Kanda-Kimura, Y Nogami, K Kohara, S Nakanishi, T Mune, K Kaku, H Kaneto
AIMS: It is well-known that chronic exposure to large amounts of ligand leads to downregulation of its receptor. It is not known, however, whether a GLP-1R agonist downregulates its receptor. For this reason, our study examined whether GLP-1R expression is reduced after long-term exposure to dulaglutide (Dula) in non-diabetic and diabetic mice. METHODS: Seven-week-old male db/db and db/m mice were given either Dula (0.6mg/kg×2/week) or a control vehicle (CTL) for 17 weeks...
February 6, 2018: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29504812/comparative-usability-study-of-the-dulaglutide-single-use-pen-versus-the-insulin-degludec-flextouch-%C3%A2-among-self-injection-na%C3%A3-ve-patients-with-type-2-diabetes-mellitus-in-japan
#13
Toshinari Asakura, Shuichi Suzuki, Toshihiko Aranishi, Zhihong Cai
OBJECTIVE: This study assessed training time with the dulaglutide single-use pen (SUP) and the insulin degludec disposable prefilled pen (FlexTouch® ) in self-injection-naïve patients with type 2 diabetes mellitus (T2DM) in Japan. METHODS: This multi-center, open-label, comparative, crossover study measured training time with the dulaglutide SUP vs FlexTouch® . Participants learned how to use both devices in a randomly assigned order. Healthcare providers (HCP) conducted the training...
March 12, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29483060/dulaglutide-as-add-on-therapy-to-sglt2-inhibitors-in-patients-with-inadequately-controlled-type-2-diabetes-award-10-a-24-week-randomised-double-blind-placebo-controlled-trial
#14
Bernhard Ludvik, Juan P Frías, Francisco J Tinahones, Julio Wainstein, Honghua Jiang, Kenneth E Robertson, Luis-Emilio García-Pérez, D Bradley Woodward, Zvonko Milicevic
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce bodyweight in patients with type 2 diabetes through different mechanisms. We assessed the safety and efficacy of the addition of the once-weekly GLP-1 receptor agonist dulaglutide to the ongoing treatment regimen in patients whose diabetes is inadequately controlled with SGLT2 inhibitors, with or without metformin. METHODS: AWARD-10 was a phase 3b, double-blind, parallel-arm, placebo-controlled, 24-week study done at 40 clinical sites in Austria, Czech Republic, Germany, Hungary, Israel, Mexico, Spain, and the USA...
May 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29430801/dulaglutide-1-5-mg-as-an-add-on-option-for-patients-uncontrolled-on-insulin-subgroup-analysis-by-age-duration-of-diabetes-and-baseline-glycated-haemoglobin-concentration
#15
Kevin M Pantalone, Hiren Patel, Maria Yu, Laura Fernández Landó
AIMS: To assess efficacy and safety of dulaglutide 1.5 mg combined with insulin, categorized by subgroups of baseline glycated haemoglobin (HbA1c; ≤9% and >9% [≤74.9 and >74.9 mmol/mol]), age (<65 and ≥65 years), and duration of diabetes (<10 and ≥10 years) at 6 months in patients with type 2 diabetes (T2D). MATERIALS AND METHODS: This pooled analysis was conducted in a population of patients with T2D with similar baseline characteristics who were included in the AWARD-4 and AWARD-9 clinical trials and randomized to dulaglutide 1...
February 12, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29397376/semaglutide-versus-dulaglutide-once-weekly-in-patients-with-type-2-diabetes-sustain-7-a-randomised-open-label-phase-3b-trial
#16
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen
BACKGROUND: Despite common mechanisms of actions, glucagon-like peptide-1 receptor agonists differ in structure, pharmacokinetic profile, and clinical effects. This head-to-head trial compared semaglutide with dulaglutide in patients with inadequately controlled type 2 diabetes. METHODS: This was an open-label, parallel-group, phase 3b trial done at 194 hospitals, clinical institutions or private practices in 16 countries. Eligible patients were aged 18 years or older and had type 2 diabetes with HbA1c 7·0-10·5% (53·0-91·0 mmol/mol) on metformin monotherapy...
April 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29377522/dulaglutide-treatment-results-in-effective-glycaemic-control-in-latent-autoimmune-diabetes-in-adults-lada-a-post-hoc-analysis-of-the-award-2-4-and-5-trials
#17
Paolo Pozzilli, Richard D Leslie, Anne L Peters, Raffaella Buzzetti, Sudha S Shankar, Zvonko Milicevic, Imre Pavo, Jeremie Lebrec, Sherry Martin, Nanette C Schloot
AIMS: Patients with a type-2-diabetes (T2D) phenotype positive for glutamic acid decarboxylase antibodies (GADA) represent the majority of cases of latent autoimmune diabetes of the adult (LADA). The GLP-1 receptor agonist dulaglutide, recently introduced for treatment of T2D, has yet to be evaluated in LADA patients. Our primary objective was to evaluate the effect of dulaglutide on glycaemic control (HbA1c) in GADA-positive LADA vs GADA-negative T2D patients. METHODS: A post-hoc analysis was performed using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D...
January 27, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29366733/improved-glycemic-control-with-once-weekly-dulaglutide-in-addition-to-insulin-therapy-in-type-2-diabetes-mellitus-patients-on-hemodialysis-evaluated-by-continuous-glucose-monitoring
#18
Takahiro Yajima, Kumiko Yajima, Makoto Hayashi, Hiroshi Takahashi, Keigo Yasuda
AIMS: To evaluate the efficacy and safety of adding once-weekly dulaglutide to insulin therapy in type 2 diabetes mellitus (T2DM) patients on hemodialysis. METHODS: Fifteen insulin-treated T2DM patients on hemodialysis were enrolled. Continuous glucose monitoring was performed before (1st hospitalization) and after the fifth dulaglutide administration (2nd hospitalization). The insulin dose was reduced after the first administration of dulaglutide (1st hospitalization day 6)...
March 2018: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/29357718/the-cost-effectiveness-of-dulaglutide-versus-insulin-glargine-for-the-treatment-of-type-2-diabetes-mellitus-in-japan
#19
Hitoshi Ishii, Matthew Madin-Warburton, Alena Strizek, Lucy Thornton-Jones, Shuichi Suzuki
AIMS: Dulaglutide is a new once weekly glucagon-like peptide-1 (GLP-1) receptor agonist administered via a disposable auto-injection pen for the management of type 2 diabetes mellitus (T2DM). The objective of this study was to estimate the cost-effectiveness of dulaglutide vs insulin glargine for the management of T2DM from a Japanese healthcare perspective, in accordance with recently approved Japanese Cost-Effectiveness Guidelines. METHODS: The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine...
May 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29355505/glutazumab-a-novel-long-lasting-glp-1-anti-glp-1r-antibody-fusion-protein-exerts-anti-diabetic-effects-through-targeting-dual-receptor-binding-sites
#20
Caina Li, Miaomiao Yang, Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Sujuan Sun, Quan Liu, Hao Pan, Shuainan Liu, Yi Huan, Shengnan Li, Jun Cao, Xing Wang, Yong Guo, Nan Guo, Shuqian Jing, Cheng Zhang, Zhufang Shen
AIMS: Glucagon like-peptide-1 (GLP-1)-based drugs have been proposed as mono- or combined therapy for type 2 diabetes mellitus. Thus we characterized a novel antibody fusion protein engineered by linking the human GLP-1 derivative to a humanized GLP-1 receptor (GLP-1R) antibody via a peptide linker. MATERIALS AND METHODS: Glutazumab was characterized by receptor binding and reporter activation assays, and its specificity was investigated with the aid of the cognate receptor antagonist exendin (9-39) and antibody Ab1...
April 2018: Biochemical Pharmacology
keyword
keyword
27533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"